信隆健康(002105) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥271,574,492.33, a decrease of 46.89% compared to ¥511,351,040.77 in the same period last year[4] - Net profit attributable to shareholders was ¥12,528,280.11, down 72.40% from ¥45,395,423.02 year-on-year[4] - Total operating revenue for Q1 2023 was CNY 271,574,492.33, a decrease of 47.9% compared to CNY 511,351,040.77 in the same period last year[17] - Net profit for Q1 2023 was CNY 12,781,217.11, a decline of 75.5% compared to CNY 51,929,752.23 in Q1 2022[18] - The total comprehensive income attributable to the parent company for Q1 2023 was CNY 10,517,590.82, compared to CNY 45,469,270.52 in the previous period, indicating a significant decrease[19] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 425.19% to ¥80,085,514.51, compared to ¥15,248,893.03 in Q1 2022[4] - The company's cash and cash equivalents increased to CNY 520,000,880.37 from CNY 505,723,313.00, reflecting a growth of 2.5%[16] - The net cash flow from investing activities was -CNY 6,116,085.50, an improvement from -CNY 14,125,948.38 in the previous year[21] - The cash flow from financing activities showed a net outflow of -CNY 55,801,251.73, compared to a slight inflow of CNY 35,192.25 in the previous year[21] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥1,780,277,597.94, a decrease of 7.09% from ¥1,916,185,931.79 at the end of the previous year[4] - Total liabilities decreased to CNY 699,226,408.37 from CNY 843,848,394.70, a decline of 17.1%[16] - The company reported a significant reduction in accounts receivable by 17.73%, from ¥371,864,562.22 to ¥305,946,991.16[6] - Inventory decreased by 19.64%, from ¥303,181,416.83 to ¥243,642,202.71, indicating a reduction in stock levels[6] - The company experienced a 21.05% decrease in short-term borrowings, from ¥383,970,584.26 to ¥303,130,449.86[6] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21,100[9] - Li Tian Development Co., Ltd. holds 41.93% of shares, totaling 154,522,500 shares[9] - The top ten shareholders do not participate in margin trading[9] - The company has a total of 4,001,100 shares held in a repurchase account[9] Compensation and Obligations - The net profit attributable to the parent company for Tian Teng Power Company in 2021 was RMB 3,800,000, while it was -RMB 1,429,110 in 2021, failing to meet performance commitments[11][13] - Tian Teng Power's original shareholders are obligated to compensate for the shortfall in net profit, with a total compensation amount of RMB 1,763,030 due for 2020 and 2021[13] - The company has not yet received the cash compensation of RMB 1,763,030 and is actively pursuing it[13] - The company received a cash compensation of RMB 606,480 for the shortfall in 2019 from Tian Teng Power's original shareholders[12] Other Financial Metrics - The company's basic earnings per share dropped to ¥0.034, down 72.80% from ¥0.125 in the same quarter last year[4] - The weighted average return on equity decreased to 1.29%, down 3.89% from 5.18% year-on-year[4] - The company reported a decrease in research and development expenses to CNY 9,657,865.39 from CNY 13,527,905.35, a decline of 28.0%[18] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.034, down from CNY 0.125 in the previous period[19] Audit Status - The report for Q1 2023 was not audited[22]